International Journal of Nanomedicine最新文献

{"title":"Significantly Increased Aqueous Solubility of Piperine via Nanoparticle Formulation Serves as the Most Critical Factor for Its Brain Uptake Enhancement.","authors":"Jiahao Li, Sharon Shui Yee Leung, Edwin Ho Yin Chan, Cuiping Jiang, Evelyn Tze Yin Ho, Zhong Zuo","doi":"10.2147/IJN.S506827","DOIUrl":"10.2147/IJN.S506827","url":null,"abstract":"<p><strong>Introduction: </strong>Piperine, the major component in <i>Piper retrofractum</i> and <i>Piper nigrum</i>, had potential therapeutic effects on central nervous system diseases such as Alzheimer's disease, Parkinson's disease, epilepsy and fragile X-associated tremor/ataxia syndrome. However, its low aqueous solubility (0.04 mg/mL) limits brain uptake and pharmacological investigations at higher doses. In the current study, formulation strategies and routes of administration were assessed to enhance systemic and brain uptake of piperine.</p><p><strong>Methods: </strong>Formulation of piperine nanoparticles (PIP NPs) was developed to enhance its solubility. PIP NPs were prepared using flash nanoprecipitation via a four-stream Multi-Inlet Vortex Mixer, employing an aqueous solution of poloxamer 188 and an ethanolic solution containing piperine and Eudragit L100-55. The process was optimized using the Design of Experiments to minimize the particle size and maximize the encapsulation efficiency of piperine. Additionally, we investigated the impact of administrating PIP NPs via oral and intranasal routes on its systemic and brain uptake.</p><p><strong>Results: </strong>The optimized PIP NPs formulation exhibited a particle size of 171.45±2.38 nm, polydispersity index of 0.27±0.01, zeta potential of -43.71±5.11 mV, encapsulation efficiency of 92.49±1.92% and drug loading of 15.07±0.09%. Fourier-transform infrared spectroscopy confirmed the successful encapsulation of piperine into nanoparticles. The PIP NPs could significantly increase the aqueous solubility of piperine from 0.04 mg/mL to 52.31±0.9 mg/mL and release piperine with a 12.83-fold higher rate than that from piperine suspension. Both oral and intranasal administrations of PIP NPs to C57BL/6 mice at 20 mg/kg demonstrated an increase in AUC_0-120min for both plasma (7.9-10 times) and brain (4.7-5.0 times) comparing to that from piperine suspension, with no significant difference between these two routes.</p><p><strong>Discussion: </strong>Our findings suggested that increasing solubility rather than changing the administration route served as the most critical step to enhance the brain uptake of piperine.</p>","PeriodicalId":14084,"journal":{"name":"International Journal of Nanomedicine","volume":"20 ","pages":"3945-3959"},"PeriodicalIF":6.6,"publicationDate":"2025-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11967364/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143779990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic Targeting in Ovarian Cancer: Nano-Enhanced CRISPR/Cas9 Gene Editing and Drug Combination Therapy.","authors":"Hong-Kook Kim, Heedon Cheong, Moo-Yeon Kim, Hyo-Eon Jin","doi":"10.2147/IJN.S507688","DOIUrl":"10.2147/IJN.S507688","url":null,"abstract":"<p><p>Ovarian cancer is the third most common gynecological cancer worldwide. Due to the high recurrence rate of advanced-stage ovarian cancer, often resulting from drug-resistant and refractory disease, various treatment strategies are under investigation. Genome editing of therapeutic target genes holds promise in enhancing cancer treatment efficacy by elucidating gene functions and mechanisms involved in cancer progression. The CRISPR/Cas9 system, in particular, shows great potential in ovarian cancer gene therapy and drug development. Targeting therapeutic genes such as BRCA1/2, P53, Snai1 etc, could improve the therapeutic strategy in ovarian cancer. CRISPR/Cas9 is a powerful gene-editing tool that there are many on-going clinical trials to treat various diseases including cancer. Nano-based delivery systems for CRISPR/Cas9 offer further therapeutic benefits, leveraging the unique properties of nanoparticles to improve delivery efficiency. Nano-based delivery systems could enhance the stability of CRISPR/Cas9 delivery formats (such as plasmid, mRNA, etc) and improve the delivery precision of delivery to target tumors. Additionally, combining CRISPR/Cas9 with targeted drug treatments, especially those aimed at genes associated with drug resistance, may significantly improve therapeutic outcomes in ovarian cancer. In this review, we discuss therapeutic target genes and their mechanisms in ovarian cancer, advances in nano-based CRISPR/Cas9 delivery, and the therapeutic potential of combining CRISPR/Cas9 with drug treatments for ovarian cancer.</p>","PeriodicalId":14084,"journal":{"name":"International Journal of Nanomedicine","volume":"20 ","pages":"3907-3931"},"PeriodicalIF":6.6,"publicationDate":"2025-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970428/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143795349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Strategy to Design Non-Symmetric Compound by Modifying the End-Group Functional Atoms for Photothermal and Photodynamic Therapy of Tumor.","authors":"Xin Xie, Jie Zeng, Miao-Yan Xu, Xin-Hao Han, Bing Fan, Xianglong Li, Duo-Duo Wei, Xiao-Jian Han, Shaorong Huang","doi":"10.2147/IJN.S509789","DOIUrl":"10.2147/IJN.S509789","url":null,"abstract":"<p><strong>Background: </strong>The exploration of non-symmetric compound for combined photothermal therapy (PTT) and photodynamic therapy (PDT) in tumor treatment remains largely unexplored.</p><p><strong>Methods: </strong>Through a molecular design strategy, a series of compound (Y-4Cl, Y-2Br, and Y-2Cl-Br) with fused - ring benzothiazole - pyrrole - thiophene - indenone constructure were synthesized to explore its phototherapy properties, to investigate their phototherapeutic properties, respectively. The non-symmetric compound Y-2Cl-Br was further formulated into nanoparticles (NPs) for detailed evaluation.</p><p><strong>Results: </strong>The non-symmetric organic compound Y-2Cl-Br demonstrated a high molar extinction coefficient (ε) of 3.0 × 10⁵ M⁻¹ cm⁻¹. Y-2Cl-Br NPs exhibited exceptional photothermal performance, including a temperature increase (ΔT) of 34 °C and a photothermal conversion efficiency (PCE) of 61.2%. Additionally, Y-2Cl-Br NPs displayed superior photostability, a reactive oxygen species (ROS) generation efficiency 9.8-fold higher than indocyanine green (ICG), remarkable fluorescence imaging (FLI) capabilities, and excellent biocompatibility.</p><p><strong>Conclusion: </strong>Both in vitro and in vivo studies confirmed that Y-2Cl-Br NPs are highly effective in PTT and PDT for tumor treatment, with minimal adverse effects. This work provides valuable insights into the design and application of non-symmetric organic compound photosensitizers (PSs) in cancer therapy.</p>","PeriodicalId":14084,"journal":{"name":"International Journal of Nanomedicine","volume":"20 ","pages":"3877-3890"},"PeriodicalIF":6.6,"publicationDate":"2025-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11967356/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143779982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dynamic Covalent Bond-Based Nanoassembly of Curcumin to Enhance the Selective Photothermal Therapy for Tumor Treatment.","authors":"Jiamin Qin, Guojuan Fan, Yanna Lv, Junxiao Zhang, Shenglin Geng, Lan Ma, Ling Wang, Jiaxin Yang, Weifen Zhang, Yizhou Zhan, Xiaoji Wang, Jinlong Ma","doi":"10.2147/IJN.S512590","DOIUrl":"10.2147/IJN.S512590","url":null,"abstract":"<p><strong>Introduction: </strong>Owing to the uneven distribution of photothermal agents (PTAs), photothermal therapy (PTT) can damage normal tissues. The dynamic reversible covalent bond, which can significantly improve the oxidation stability of the drug and the characteristics of responsive drug release, thus improving the conversion efficiency of the drug, is a feasible solution to enhance the selective PTT for tumor treatment.</p><p><strong>Methods: </strong>The nanoassembly loaded curcumin (Cur) with dynamic covalent boronate and encapsulated Indocyanine Green (ICG) in the phospholipid bilayer by dynamic self-assembly.</p><p><strong>Results: </strong>The pH-responsive dynamic covalent bond-based nanoassembly system has great selective release of drugs in the tumor microenvironment and photothermal conversion efficiency. Furthermore, LIP-C/I could increase the antitumor effect through the combination of PTT and chemotherapy (CT). The experiments in vitro and in vivo have demonstrated that LIP-C/I could enhance selective PTT for tumor treatment.</p><p><strong>Discussion: </strong>Our nanoassembly system provides an alternative approach for enhancing selective PTT for tumor treatment using dynamic covalent boronate.</p>","PeriodicalId":14084,"journal":{"name":"International Journal of Nanomedicine","volume":"20 ","pages":"3861-3875"},"PeriodicalIF":6.6,"publicationDate":"2025-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11967351/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143779985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Folic Acid-Targeted Liposome-Based Nanoparticle Loaded with Sorafenib for Liver Cancer Therapy.","authors":"Songyang Liu, Dan Yi, Rui Ma, Wei Zhang","doi":"10.2147/IJN.S489777","DOIUrl":"10.2147/IJN.S489777","url":null,"abstract":"<p><strong>Introduction: </strong>Sorafenib (SF) is a small molecule involved in tumor proliferation and angiogenesis. SF is inhibitor of several kinases, including RAF, VEGFR, and PDGFR. However the weak targeting ability of SF for liver tumor tissues is the major problem in clinical therapy. Therefore, a SF-loaded folic acid-targeted liposome drug delivery system was devised for targeting liver tumor therapy in this study.</p><p><strong>Methods: </strong>Folic acid (FA), HSPC, DSPE-PEG_2k, CHO, and SF were composed to prepare a folic acid-targeted SF-loaded liposome (LSF) drug delivery system. LSF and drug loading content was established through thin-film-hydration technique and HPLC, respectively. The particle size and stability of LSF were examined by dynamic light scattering (DLS). The inhibition effect of LSF was elucidated in vitro on liver cancer cells through cell cytotoxicity and apoptosis experiments. The tumor-inhibiting efficacy was measured on liver xenograft model.</p><p><strong>Results: </strong>The drug loading content (DLC) of LSF was 3.6%. The diameter of LSF was 197.1±16.6 nm, and LSF was stable during 24 h. Liver cancer cells could be effectively inhibited by LSF in vitro. LSF could substantially induce apoptosis. Also, LSF could inhibit tumor growth effectively in vivo. LSF could reduce side effects of SF demonstrated by bio-safety tests.</p><p><strong>Conclusion: </strong>LSF is a FA-targeted drug delivery system that could effectively inhibit the progression of liver cancer.</p>","PeriodicalId":14084,"journal":{"name":"International Journal of Nanomedicine","volume":"20 ","pages":"3933-3944"},"PeriodicalIF":6.6,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11963799/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143772290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Self-Regulating Doped Ferrite Nanoparticles with Glucose, Chitosan, and Poly-Ethylene Glycol Coatings for Hyperthermia and Dual Imaging.","authors":"Alessandro Negri, Anita Conti, Emil Milan, Enrico Forlin, Filippo Gherlinzoni, Giovanni Morana, Michele Gottardi, Paolo Matteazzi, Adolfo Speghini, Andre Bongers, Pasquina Marzola","doi":"10.2147/IJN.S506443","DOIUrl":"10.2147/IJN.S506443","url":null,"abstract":"<p><strong>Purpose: </strong>This study investigates the theranostic potential of doped ferrite nanoparticles (NPs) with self-regulating temperature (SRT) properties, termed M55, coated with glucose (GM55), chitosan (CM55), and poly-ethylene glycol (PM55). The NPs were assessed for their physicochemical attributes, magnetic fluid hyperthermia (MFH) efficacy, dual-imaging capabilities in Magnetic Resonance Imaging (MRI) and Magnetic Particle Imaging (MPI), cytocompatibility, and cellular uptake.</p><p><strong>Methods: </strong>Physicochemical characterization was conducted using Fourier-transform infrared spectroscopy (FTIR), dynamic light scattering (DLS), and zeta potential measurements. The biocompatibility and cellular uptake were evaluated in MDA-MB-231 breast cancer cells, and MFH performance was tested in vitro. Following intravenous administration, MRI and MPI functionalities were analyzed through phantom studies and in vivo murine models.</p><p><strong>Results: </strong>Coated M55 NPs displayed high colloidal stability in water and effective functionalization. The specific absorption rate (SAR) of 24.4 ± 1.4 W/g confirmed their suitability for MFH applications. In vitro assays indicated excellent biocompatibility and substantial cellular internalization, with GM55 showing the highest uptake and MFH efficiency, reducing cell viability to 50.62 ± 3.92% post two treatment cycles, compared to 67.71 ± 6.11% (CM55) and 71.39 ± 5.84% (PM55). MRI transverse relaxivity (r₂) values were notably high across all coatings, enhancing imaging contrast. MPI analysis demonstrated superior cell labeling sensitivity, with GM55 achieving the most pronounced detection. In vivo imaging confirmed effective NPs accumulation in the liver, underscoring their utility as dual MRI/MPI contrast agents (CAs).</p><p><strong>Conclusion: </strong>Coated M55 NPs exhibit significant promise as multifunctional theranostic agents for cancer treatment. GM55, in particular, offers superior MFH efficacy and cellular uptake, while CM55 and PM55 may present unique advantages for alternative biomedical applications. The dual-imaging capabilities of these NPs provide a robust platform for real-time monitoring of distribution and therapeutic outcomes. Future investigations will focus on optimizing NPs formulations and expanding in vivo assessments to advance clinical translation.</p>","PeriodicalId":14084,"journal":{"name":"International Journal of Nanomedicine","volume":"20 ","pages":"3891-3906"},"PeriodicalIF":6.6,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11963800/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143772346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dual-Mode Treatment of Hepatocellular Carcinoma Using RGD Cyclopeptide-Modified Liposomes Loaded with Ce6/DOX.","authors":"Wentao Xu, Jiajia Zheng, Jiaqi Zhang, Houhui Shi, Weili Peng, Yang Liu, Guodong Feng, Yuguang Wang, Yi-Jun Liang, Jun Chen","doi":"10.2147/IJN.S509387","DOIUrl":"10.2147/IJN.S509387","url":null,"abstract":"<p><strong>Background: </strong>Liver cancer is one of the most prevalent cancers globally, with approximately 90% of primary liver cancers being hepatocellular carcinomas (HCC). However, current systemic treatment options (whether monotherapy or combination therapy) are limited and offer only modest survival benefits. The effectiveness of a drug is largely determined by its concentration at the target site. Therefore, an effective drug delivery system must enhance drug accumulation at the target site, enable selective drug release there, and facilitate escape from lysosomes.</p><p><strong>Methods: </strong>cRGD-Lipo@Ce6/DOX was prepared by modifying c(RGDyK) onto the surface of drug-loaded liposomes containing Chlorin e6 (Ce6) and doxorubicin (DOX) through an amide reaction. The targeting capability and uptake mechanism of cRGD-Lipo@Ce6/DOX for HCC were analyzed using flow cytometry. To investigate drug release mechanisms and changes in subcellular distribution following ultrasound stimulation, further studies were conducted. The therapeutic efficacy and biosafety of this dual-modality therapy were then evaluated in an HCC subcutaneous tumor-bearing mouse model.</p><p><strong>Results: </strong>The prepared nanocomplex exhibits a surface charge of -9.91 ± 2.94 mV and an apparent size of 118.07 ± 1.46 nm. Modification of the RGD cyclic peptide on the surface of the drug-carrying liposomes enhanced the targeting and penetration efficiency for HCC. In vitro experiments on drug uptake mechanisms and release demonstrated that reactive oxygen species (ROS) generated by sonodynamic therapy (SDT) promote effective drug release from the carrier into the non-lysosomal region. The combined SDT and chemotherapy treatment achieved a 94% tumor inhibition rate and showed excellent biosafety in HCC subcutaneous tumor-bearing mice.</p><p><strong>Conclusion: </strong>Therefore, the effectiveness of the combination treatment strategy utilizing SDT in conjunction with chemotherapy provides additional treatment options for patients with HCC.</p>","PeriodicalId":14084,"journal":{"name":"International Journal of Nanomedicine","volume":"20 ","pages":"3845-3860"},"PeriodicalIF":6.6,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11956788/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gold Nanoparticles Enhance TRAIL Sensitivity Through Drp1-Mediated Apoptotic and Autophagic Mitochondrial Fission in NSCLC Cells [Retraction].","authors":"","doi":"10.2147/IJN.S530388","DOIUrl":"https://doi.org/10.2147/IJN.S530388","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.2147/IJN.S129274.].</p>","PeriodicalId":14084,"journal":{"name":"International Journal of Nanomedicine","volume":"20 ","pages":"3843-3844"},"PeriodicalIF":6.6,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955735/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-Inflammatory Combination of Puerarin and Ac2-26 Using Intranasal Delivery for Effective Against Ischemic Stroke in Rat Model.","authors":"Guangzhe Xu, Chun Ma, Hongyan Chu, Wenxin Hu, Lihua Yang, Shuling Li","doi":"10.2147/IJN.S508800","DOIUrl":"10.2147/IJN.S508800","url":null,"abstract":"<p><strong>Purpose: </strong>The pathological mechanisms underlying ischemic stroke are highly complex, with the neuroinflammatory response triggered by cerebral ischemia-reperfusion being a major contributor to secondary brain damage. This response significantly impedes neural tissue regeneration. Despite advancements in treatment, current anti-inflammatory strategies remain suboptimal in terms of safety and efficacy. This study aimed to develop an all-natural nanomedicine delivery system for the transnasal administration of puerarin, combined with the endogenous anti-inflammatory peptide Ac2-26, to enhance neuroprotection against ischemic stroke through a synergistic anti-inflammatory approach.</p><p><strong>Methods: </strong>In this study, collagen nanoparticles (PueNps) loaded with puerarin were synthesized, followed by the preparation of a chitosan hydrogel. The PueNps and Ac2-26 were co-encapsulated within the hydrogel, resulting in the formation of the PueNps&Ac2-26 gel formulation. The physicochemical properties of this formulation, as well as its biodistribution and anti-ischemic efficacy in the MCAO rat brain, were evaluated.</p><p><strong>Results: </strong>In this formulation system, the bioavailability of puerarin and Ac2-26 was enhanced, exhibiting sustained-release properties, which enabled efficient brain-targeted delivery. It effectively alleviated neurological impairment in MCAO rats, reduced the volume of cerebral infarction, and decreased brain water content. Additionally, the PueNps&Ac2-26 gel significantly inhibited neuroinflammation in rats and alleviated oxidative stress.</p><p><strong>Conclusion: </strong>The PueNps&Ac2-26 gel is a purely natural and efficient formulation system, offering a promising approach for the clinical treatment of ischemic stroke in the future.</p>","PeriodicalId":14084,"journal":{"name":"International Journal of Nanomedicine","volume":"20 ","pages":"3825-3842"},"PeriodicalIF":6.6,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11954400/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic Nanomaterials in NAFLD: Current Advances and Potential Applications in Patients with Concurrent HBV Infection.","authors":"Guixin Li, Zheng Dai, Jinghui Guo","doi":"10.2147/IJN.S510271","DOIUrl":"10.2147/IJN.S510271","url":null,"abstract":"<p><p>Due to the high prevalence of non-alcoholic fatty liver disease (NAFLD) and chronic hepatitis B virus (HBV) infection, a significant proportion of patients suffer from both conditions simultaneously. The management of NAFLD in patients with concurrent HBV infection presents unique challenges, primarily due to the complex interplay between these two diseases. Nanomaterials have gained widespread attention due to their ability to overcome the limitations of conventional therapies. This review provides an overview of the current advances in therapeutic nanomaterials for NAFLD and explores their potential applications for personalized and effective management in patients with concurrent HBV infection. Furthermore, we discuss the challenges and future directions in the development of nanomaterials for the treatment of coexisting liver diseases.</p>","PeriodicalId":14084,"journal":{"name":"International Journal of Nanomedicine","volume":"20 ","pages":"3803-3823"},"PeriodicalIF":6.6,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11954402/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}